Article | Published:

In vivo genome editing using Staphylococcus aureus Cas9

Nature volume 520, pages 186191 (09 April 2015) | Download Citation

Abstract

The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Primary accessions

BioProject

Data deposits

All reagents described in this manuscript have been deposited with Addgene (plasmid IDs 61591, 61592 and 61593). Source data are available online and deep sequencing data are available at Sequence Read Archive under BioProject accession number PRJNA274149.

References

  1. 1.

    , , & Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151, 2551–2561 (2005)

  2. 2.

    et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709–1712 (2007)

  3. 3.

    et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67–71 (2010)

  4. 4.

    et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602–607 (2011)

  5. 5.

    et al. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res. 39, 9275–9282 (2011)

  6. 6.

    et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012)

  7. 7.

    , , & Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl Acad. Sci. USA 109, E2579–E2586 (2012)

  8. 8.

    et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013)

  9. 9.

    et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013)

  10. 10.

    et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler. Suppl. 11, 55–60 (2010)

  11. 11.

    & Precise hit: adeno-associated virus in gene targeting. Nature Rev. Microbiol. 3, 837–847 (2005)

  12. 12.

    & Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Rev. Genet. 12, 341–355 (2011)

  13. 13.

    , & New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285–297 (2005)

  14. 14.

    State-of-the-art gene-based therapies: the road ahead. Nature Rev. Genet. 12, 316–328 (2011)

  15. 15.

    , , & Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073–1080 (2008)

  16. 16.

    et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nature Biotechnol. 33, 102–106 (2015)

  17. 17.

    et al. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol. J. 9, 1402–1412 (2014)

  18. 18.

    et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935–949 (2014)

  19. 19.

    , , & Classification and evolution of type II CRISPR-Cas systems. Nucleic Acids Res. 42, 6091–6105 (2014)

  20. 20.

    , & The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol. 10, 726–737 (2013)

  21. 21.

    , & Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014)

  22. 22.

    et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nature Biotechnol. 31, 827–832 (2013)

  23. 23.

    et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl Acad. Sci. USA 110, 15644–15649 (2013)

  24. 24.

    , , , & Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nature Biotechnol. 32, 279–284 (2014)

  25. 25.

    et al. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc. Natl Acad. Sci. USA 108, 10098–10103 (2011)

  26. 26.

    et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnol. 31, 822–826 (2013)

  27. 27.

    et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnol. 31, 833–838 (2013)

  28. 28.

    et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nature Biotechnol. 31, 839–843 (2013)

  29. 29.

    et al. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 42, 7473–7485 (2014)

  30. 30.

    , & Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473–1475 (2014)

  31. 31.

    et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nature Biotechnol. 32, 670–676 (2014)

  32. 32.

    , , , & Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nature Biotechnol. 32, 677–683 (2014)

  33. 33.

    et al. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nature Methods 10, 361–365 (2013)

  34. 34.

    Recent progress in understanding apolipoprotein B. Circulation 82, 1574–1594 (1990)

  35. 35.

    et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004)

  36. 36.

    et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104, 12982–12987 (2007)

  37. 37.

    et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnol. 25, 1149–1157 (2007)

  38. 38.

    et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383, 60–68 (2014)

  39. 39.

    et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genet. 34, 154–156 (2003)

  40. 40.

    et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature Genet. 37, 161–165 (2005)

  41. 41.

    , & Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32, 71–77 (2007)

  42. 42.

    et al. Guide RNA functional modules direct Cas9 activity and orthogonality. Mol. Cell 56, 333–339 (2014)

  43. 43.

    et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nature Biotechnol. 33, 187–197 (2015)

  44. 44.

    et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nature Biotechnol. 33, 179–186 (2015)

  45. 45.

    , , & WebLogo: a sequence logo generator. Genome Res. 14, 1188–1190 (2004)

  46. 46.

    & Direct RNA motif definition and identification from multiple sequence alignments using secondary structure profiles. J. Mol. Biol. 313, 1003–1011 (2001)

  47. 47.

    et al. RNAMotif, an RNA secondary structure definition and search algorithm. Nucleic Acids Res. 29, 4724–4735 (2001)

  48. 48.

    et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 9, R137 (2008)

  49. 49.

    et al. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther. 6, 272–278 (2002)

  50. 50.

    Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406–3415 (2003)

Download references

Acknowledgements

We thank E. Charpentier, I. Fonfara and K. Chylinski for discussions; A. Scherer-Hoock, B. Clear and the MIT Division of Comparative Medicine for assistance with animal experiments; Boston Children’s Hospital Viral Core and R. Xiao for assistance with AAV production; N. Crosetto for advice on BLESS; C.-Y. Lin and I. Slaymaker for experimental assistance; and the entire Zhang laboratory for support and advice. F.A.R. is a Junior Fellow at the Harvard Society of Fellows. W.X.Y. is supported by T32GM007753 from the National Institute of General Medical Sciences and a Paul and Daisy Soros Fellowship. J.S.G. is supported by a US Department of Energy Computational Science Graduate Fellowship. X.W. is a Howard Hughes Medical Institute International Student Research Fellow. P.A.S. is supported by United States Public Health Service grants RO1-GM34277, R01-CA133404 from the National Institutes of Health, and PO1-CA42063 from the National Cancer Institute, and partially by Cancer Center Support (core) grant P30-CA14051 from the National Cancer Institute. F.Z. is supported by the National Institutes of Health through NIMH (5DP1-MH100706) and NIDDK (5R01DK097768-03), a Waterman Award from the National Science Foundation, the Keck, New York Stem Cell, Damon Runyon, Searle Scholars, Merkin, and Vallee Foundations, and B. Metcalfe. F.Z. is a New York Stem Cell Foundation Robertson Investigator. The Children’s Hospital virus core is supported by an NIH core grant (5P30EY012196-17). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health. CRISPR reagents are available to the academic community through Addgene, and information about the protocols, plasmids, and reagents can be found at the Zhang laboratory website http://www.genome-engineering.org.

Author information

Author notes

    • F. Ann Ran
    • , Le Cong
    •  & Winston X. Yan

    These authors contributed equally to this work.

Affiliations

  1. Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA

    • F. Ann Ran
    • , Le Cong
    • , Winston X. Yan
    • , David A. Scott
    • , Jonathan S. Gootenberg
    • , Bernd Zetsche
    • , Ophir Shalem
    •  & Feng Zhang
  2. Society of Fellows, Harvard University, Cambridge, Massachusetts 02138, USA

    • F. Ann Ran
  3. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

    • Le Cong
    • , Andrea J. Kriz
    •  & Phillip A. Sharp
  4. Graduate Program in Biophysics, Harvard Medical School, Boston, Massachusetts 02115, USA

    • Winston X. Yan
  5. Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts 02115, USA

    • Winston X. Yan
  6. McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

    • David A. Scott
    •  & Feng Zhang
  7. Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

    • David A. Scott
    •  & Feng Zhang
  8. Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA

    • Jonathan S. Gootenberg
  9. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

    • Xuebing Wu
    •  & Phillip A. Sharp
  10. Computational and Systems Biology Graduate Program, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

    • Xuebing Wu
  11. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland 20894, USA

    • Kira S. Makarova
    •  & Eugene V. Koonin
  12. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

    • Feng Zhang

Authors

  1. Search for F. Ann Ran in:

  2. Search for Le Cong in:

  3. Search for Winston X. Yan in:

  4. Search for David A. Scott in:

  5. Search for Jonathan S. Gootenberg in:

  6. Search for Andrea J. Kriz in:

  7. Search for Bernd Zetsche in:

  8. Search for Ophir Shalem in:

  9. Search for Xuebing Wu in:

  10. Search for Kira S. Makarova in:

  11. Search for Eugene V. Koonin in:

  12. Search for Phillip A. Sharp in:

  13. Search for Feng Zhang in:

Contributions

F.A.R. and F.Z. conceived this study. F.A.R., L.C., W.X.Y. and F.Z. designed and performed the experiments with help from all authors. F.A.R., J.S.G., O.S., K.S.M., E.V.K. and F.Z. contributed to analysis of Cas9 orthologues, crRNA and tracrRNA, and PAM. A.J.K., F.A.R., X.W., and P.A.S. led ChIP and computational analysis and validation. F.A.R., W.X.Y. and L.C. performed BLESS and targeted sequencing of BLESS-identified off-target sites, and D.A.S. contributed computational analysis of BLESS data. W.X.Y., F.A.R., L.C. and B.Z. contributed animal data. W.X.Y., F.A.R., L.C., J.S.G., and F.Z. wrote the manuscript with help from all authors.

Competing interests

Patent applications have been filed as to the subject matter of the manuscript such as, for example, US patent 8,865,406 issued 21 October 2014 and US patent 8,895,308 issued 25 November 2014. F.Z. is a founder of Editas Medicine and scientific advisor for Editas Medicine and Horizon Discovery.

Corresponding author

Correspondence to Feng Zhang.

Extended data

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains a Supplementary Discussion, Supplementary References, Supplementary Tables 1-9 and Supplementary Sequences.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature14299

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.